



Corporate Announcement

Neugenesis to present at the Chemical and Biological Defense - Science and Technology Conference

Burlingame, California, November 16, 2009

Debbie Higgins, Director - Vaccine Research and Development at Neugenesis Corporation will be presenting at the Chemical and Biological Defense - Science and Technology Conference to be held in Dallas, Texas from November 16-20, 2009. The latest developments of the medical and physical science disciplines of chemical and biological defense for the warfighter will be showcased simultaneously. The Neugenesis presentation titled "A Rapid and Inexpensive Fungal Production Platform for Producing Therapeutics and Vaccines" will be in the Vaccines and Adjuvants session on Thursday, November 19, 2009.

About Neugenesis

Neugenesis Corporation is a privately held biotechnology company which has generated a diverse set of technology platforms for the world wide biotechnology and biopharmaceutical industry. In addition to its new position in vaccines, Neugenesis is also involved in development of technology for production of monoclonal antibodies for biodefense. The Company holds strong intellectual property positions in the areas of production of recombinant monoclonal antibodies, cell based gene-directed evolution, and cell based combinatorial biology. Neugenesis is actively seeking partners in the biopharmaceutical industry to rapidly move the technology into the marketplace.

Contact Information

Laurie Fosner
Neugenesis Corporation
863 Mitten Road, Suite C
Burlingame, CA 94101
(650) 689-2220
www.neugenesis.com.

###